Compare Regeneron Pharmaceuticals Inc (REGN) vs Riot Platforms Inc (RIOT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs Riot Platforms Inc — how do they compare? Regeneron Pharmaceuticals Inc trades at $740 (market cap $76.14B), while Riot Platforms Inc trades at $17.25 (market cap $6.32B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 12× Riot Platforms Inc's market cap, and Regeneron Pharmaceuticals Inc pays a 0.51% dividend while Riot Platforms Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Regeneron Pharmaceuticals Inc for 107 Days and Riot Platforms Inc for 16 Days on average.
| REGN | RIOT | |
|---|---|---|
Market Cap | $76.14B | $6.32B |
Volume | 500,239 | 30,571,756 |
Sector | Health | Financials |
52-Week High | $852.03 | $28.67 |
52-Week Low | $557.73 | $11.83 |
Typical Hold Time | 107 Days | 16 Days |
Enterprise Value | $70.85B | $6.73B |
Dividend Yield | 0.51% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $742.12, up 0.46% on the day, with a bearish technical signal despite strong fundamentals. The stock shows robust profitability with a 27.86% net income margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights a significant $8 billion immunology alliance expansion with Sanofi, providing substantial upfront and milestone payments.
The outlook is positive due to strong earnings momentum and strategic collaborations, but risks include competitive pressures in key drug markets and technical bearish indicators. Analyst consensus is bullish with a $849.84 price target, suggesting potential upside from current levels, though investors should monitor execution of new partnerships and pipeline developments.
RIOT trades at $18.54, down 2.06% with bearish technical signals despite strong analyst support. The company shows concerning fundamentals with a -196.28% net income margin and negative cash flow from operations of -$573M in 2025. However, RIOT is pivoting to AI data center services, securing $9.8B in long-term contracts through 2048 with major tenants including AMD, potentially transforming its revenue model.
While analyst consensus remains strongly bullish with 94.74% buy ratings and $31.64 price target, investors face significant execution risks in the business model transition. The stock offers substantial upside potential if AI initiatives succeed but carries high volatility given current unprofitability and competitive pressures in both Bitcoin mining and data center markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About Riot Platforms Inc
Riot Platforms, Inc. is a Bitcoin mining company that focuses on building, operating, and expanding large-scale infrastructure for digital asset mining in North America. The company's operations include Bitcoin mining, data center hosting, and engineering solutions. Riot's strategy emphasizes vertical integration to maximize efficiency and scale its mining capacity, aiming to be a leader in the global Bitcoin and digital infrastructure industry.
Read more on RIOT →
